Navigation Links
Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
Date:11/8/2011

ANN ARBOR, Mich., Nov. 8, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that George J. Brewer, M.D., the Company's Senior Vice President of Research & Development, will be a featured speaker at the 52nd Annual Meeting of the American College of Nutrition to be held in Morristown, New Jersey, on November 16-19, 2011. Dr. Brewer is the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan.

Dr. Brewer will moderate the "Important Developments with Trace Elements" symposium with Ananda S. Prasad, M.D., Ph.D., a Distinguished Professor of Internal Medicine at Wayne State University School of Medicine and an Adeona Scientific Advisory Board member. During this symposium, Dr. Brewer will discuss the role of zinc deficiency and copper toxicity on cognitive loss and their contributions to the current epidemic of Alzheimer's disease.

Adeona also announced that, Diana Pollock, M.D., Lead Principal Investigator of the Company's clinical study that evaluated reaZin in Alzheimer's disease patients at Morton Plant Neuroscience Institute on the campus of Morton Plant Hospital, will present top-line results that demonstrated, on average, that the cognitive function (as measured by three standardized cognitive tests) of the Alzheimer's patients managed with reaZin remained relatively stable over six months, while the placebo group showed deterioration. In addition, Dr. Pollock will present the age-related subgroup analysis that showed dosing-compliant Alzheimer's patients age 70 and over demonstrated statistically significant improvements in two of the three cognitive scoring measurements in the reaZin treatment group compared to the placebo group. Adeona's product candidate, reaZin (zinc cysteine), is being developed as a medical food for the dietary management of zinc deficiency associated with Alzheimer's disease.

About the American College of Nutrition (ACN)

The mission of the ACN is to improve the quality of nutrition care by enhancing nutrition education for physicians. An integral part of ACN's education activities is providing opportunities to fill in the gaps in the current medical school curriculum as well as ongoing post-graduate training. The goal of this training is to enhance nutrition and metabolism knowledge and to promote the application of such knowledge in clinical practice for the prevention and treatment of disease. For more information about ACN, please visit the website at www.americancollegeofnutrition.org.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available: reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and wellZin™, a homeopathic over-the-counter medicine for reducing the duration and symptoms of the common cold. Adeona also operates Adeona Clinical Laboratory, a wholly owned clinical reference laboratory that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the use of zinc as a potential dietary management for cognitive deficits in Alzheimer's patients, the limitations inherent in post-hoc interpretations of clinical study results and our intent to further commercialize development of reaZin as a medical food. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, our failure to successfully commercialize reaZin for the management of Alzheimer's disease, the failure of reaZin to be accepted for dietary management of Alzheimer's disease, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona Appoints Jeff Lucero Riley as Independent Chairman
2. Adeonas Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease is Hot Topic at 2011 California ALS Research Summit
3. Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
4. Adeona Appoints George A. Eby to Scientific Advisory Board
5. Adeona Reports Second Quarter 2011 Financial Results
6. Adeona to Host Second Quarter 2011 Investor Conference Call
7. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
8. Adeona Reports 1st Quarter 2011 Financial Results
9. Adeona to Host First Quarter 2011 Investor Conference Call
10. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
11. Adeonas Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the ... Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced that it ... Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany ...
(Date:4/24/2017)... ... ... The bar for just about everything—apparel, eyewear, cars and even phone cases—is ... and film stardom.(1) Not to be left out is that most desired of commodities, ... gamut from being encrusted with jewels and precious metals to, at the very least, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer dental ... 1,961 people during the April 22-23 event at the San Mateo Event Center. ... barriers to care, CDA Cares educates the public and policymakers about the importance of ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the ... life forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her ... I began journaling conversations and situations throughout my divorce,” James said. “After the death ...
Breaking Medicine News(10 mins):